Overview

NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I study that will enroll patients with pancreatic cancer and liver metastasis who have failed prior gemcitabine-based chemotherapy. Patients will be treated with nanoliposomal irinotecan plus 5-FU and leucovorin and NH002-based sonoporation to the liver metastasis.
Phase:
PHASE1
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborator:
Trust Bio-sonics, Inc.